GenSight Biologics completes EUR 1M fundraising and lists on Euronext Paris
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
GenSight Biologics announced the successful completion of a EUR 1,000,000.208 fundraising, which was subscribed by Heights Capital and Invus. The company also announced its listing on the Euronext Paris regulated market. The fundraising is not subject to the obligation to publish a prospectus under the Prospectus Regulation.
From finanznachrichten.de
Why it matters
The listing and fundraising activity directly affects the financial market. Euronext might see increased market activity and fee revenue as a result of the company's participation.
From finanznachrichten.de
Who's involved
- EuronextThe pan-European bourse where GenSight Biologics is listing its shares
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- EuronextSpeculative
Euronext could see increased fee revenue and market activity due to the successful listing and fundraising.